Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2005 -- Ignore unavailable to you. Want to Upgrade?

To: michael_f_murphy who wrote (35)	1/1/2005 7:18:10 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 322

Arius Research Reasons for inclusion: 1. Humanized Monoclonal Antibody company 2. Cancer Program 3. Screens first for tumor cell-killing 4. Development partnerships with PDLI, (some English Co with nothing near term), and Xenergen (sp.) 5. HuMab pship with Medarex 6. Famous investors include BVF, with 49% fully diluted, and me 7. Lead collaborative program, anti-CD44, goes into clinic this year. I don’t really want to say it, BUT…a certain CD44 isoform could be a breast cancer stem cell marker. OK…I do doubt Aruius has THE Mab for it, but I guarantee someone will bring up the possibility at a timely moment. 8. The company just can’t continue the way it has Reason for exclusion: 1. It IS thinly traded—nearly by appointment--and took me two good-till-canceled orders over 45 days to buy a half position in the PA. For this reason I would accept your decision that it be replaced. I will truly honestly happily accept your decision whatever comes. Of course any idiot can see it is more in keeping with a Biotech Contest than that mutual fund that peoples try to... kid us....with.